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Immediate β2-integrin activation upon T cell receptor stimulation is
critical for effective interaction between T cells and their targets
and may therefore be used for the rapid identification and iso-
lation of functional T cells. We present a simple and sensitive flow
cytometry-based assay to assess antigen-specific T cells using fluo-
rescent intercellular adhesion molecule (ICAM)-1 multimers that
specifically bind to activated β2-integrins. The method is compati-
ble with surface and intracellular staining; it is applicable for mon-
itoring of a broad range of virus-, tumor-, and vaccine-specific
CD8+ T cells, and for isolating viable antigen-reacting cells. ICAM-1
binding correlates with peptide-MHCmultimer binding but, notably,
it identifies the fraction of antigen-specific CD8+ T cells with imme-
diate and high functional capability (i.e., expressing high levels of
cytotoxic markers and cytokines). Compared with the currently
available methods, staining of activated β2-integrins presents the
unique advantage of requiring activation times of only several
minutes, therefore delivering functional information nearly reflect-
ing the in vivo situation. Hence, the ICAM-1 assay is most suitable
for rapid and precise monitoring of functional antigen-specific T cell
responses, including for patient samples in a variety of clinical set-
tings, as well as for the isolation of functional T cells for adoptive
cell-transfer immunotherapies.
antigen-specific T cells | ICAM-1 multimers | integrins | flow cytometry cell
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T cell immunity plays a crucial role in the immune defenseagainst pathogens and tumors. Assessment of T cell fre-
quencies, phenotypes, and functionality is essential to monitor
antigen-specific immune responses and to identify correlates of
protection after vaccination or during therapy (1). Upon T cell
receptor (TCR) engagement by cognate antigens, T lymphocytes
up-regulate a number of activation markers and develop multiple
effector functions, including proliferation, cytotoxicity, and cy-
tokine production. One method of choice for identification of
antigen-specific T cells is the use of fluorescent peptide-MHC
multimers (pMHC multimers). While this method has revolu-
tionized our understanding of antigen-specific T cells, it does
not provide direct information on their function (2, 3). There-
fore, the quality of the T cell response is additionally assessed
by up-regulation of activation markers (e.g., CD154/CD137),
CD107a surface expression, or cytokine/chemokine production
(4–7). However, addressing these functional attributes requires
several hours of stimulation with antigens and elaborated
protocols.
Another functional property of T lymphocytes that has not yet
been used as a monitoring tool for antigen-specific cells is the
activation of integrins upon TCR engagement (8). Resting,
antigen-experienced T lymphocytes express high levels of membrane-
bound β2-integrins (9, 10); however, these are maintained in a
nonadhesive state (11). Following TCR-mediated stimulation,
integrin activation occurs within seconds through a process known
as “inside-out” signaling that leads to an affinity increase and
clustering of membrane-bound integrins. This jointly enhanced
avidity is critical for effective interaction between T cells and their
targets, a process essential for execution of effector functions (12–
15). We aimed to establish a flow cytometry assay that detects
integrin activation on antigen-specific T cells. To overcome the
problem that the interaction between β2-integrins and the sol-
uble monomeric or dimeric form of intercellular adhesion
molecule 1 (ICAM-1) is very weak and unstable, we produced
multimeric ICAM-1–Fc/anti–Fc-fluorochrome complexes by mixing
recombinant human ICAM-1–Fc with goat anti-human Fc
F(ab′)2 fluorochrome-labeled fragments (hereafter referred to as
mICAM-1) (16–18).
In this study, we establish activated integrins as an ideal marker
for the rapid, sensitive, and selective identification of CD8+ T cells
reacting to a broad range of antigens, like the superantigen
staphylococcal enterotoxin B (SEB), as well as peptides from
cytomegalovirus (CMV), Epstein-Barr virus (EBV), influenza
virus (Flu), HIV, yellow fever virus (YFV), and tumor-associated
antigens. By comparing the mICAM-1 method with the pMHC
Significance
Assessing antigen-specific T cells is crucial for our understand-
ing of immune reactions against pathogens and tumors, and
for evaluating immunotherapies in patients. Existing tech-
niques to evaluate the functionality of T lymphocytes all rely
on de novo expression of proteins, typically intracellular cyto-
kines, and therefore require elaborated protocols and re-
agents. We have established a simple flow cytometry-based
method to assess the functionality of CD8+ T cells by identi-
fying immediate changes in the conformation and valency of
cell surface integrins that occur within minutes following an-
tigenic stimulation. Because of its robustness, sensitivity, and
broad applicability, the assay can be rapidly implemented for
the measurement and isolation of functional T cells for basic
research and in the clinical setting.
Author contributions: S.D., C.G., L.B., P.A.C., M.S., T.L., J.B., and H.-G.R. designed research;
S.D., C.G., L.B., P.A.C., E.R., and R.B. performed research; A.T.R.J. contributed new re-
agents/analytic tools; S.D. analyzed data; S.D. prepared figures; and S.D., C.G., T.L., J.B.,
and H.-G.R. wrote the paper.
The authors declare no conflict of interest.
This article is a PNAS Direct Submission.
This open access article is distributed under Creative Commons Attribution-NonCommercial-
NoDerivatives License 4.0 (CC BY-NC-ND).
1To whom correspondence may be addressed. Email: stoyan.dimitrov@uni-tuebingen.de,
cecile.gouttefangeas@uni-tuebingen.de, or rammensee@uni-tuebingen.de.
2T.L., J.B., and H.-G.R. contributed equally to this work.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.
1073/pnas.1720714115/-/DCSupplemental.
Published online May 29, 2018.
E5536–E5545 | PNAS | vol. 115 | no. 24 www.pnas.org/cgi/doi/10.1073/pnas.1720714115
multimer and intracellular staining assays, we show that mICAM-
1 multimers identify the fraction of pMHC+ CD8+ T cells, which
predominantly produce cytokines and cytotoxic markers upon
antigen stimulation. We also demonstrate that the assay is suitable
for the isolation of viable antigen-specific CD8+ T cells that can be
readily expanded in vitro while maintaining functionality. Notably,
due to its simplicity and robustness, mICAM-1 staining is especially
appropriate to quickly assess functional antigen-specific T cells in
patient samples.
Results
Antigen-Specific β2-Integrin Activation on CD8+ T Cells Can Be
Visualized by mICAM-1 Binding. We investigated the feasibility of
using mICAM-1 complexes as a staining reagent for antigen-
specific CD8+ T cells. First, we assessed the kinetics of β2-
integrin activation and mICAM-1 binding to determine the op-
timal duration for cell stimulation (Fig. 1). Whole blood—the
main source of cells used in this study—from one to three se-
lected HLA-A2+ donors (hereafter referred to as A2+donors)
was stimulated with antigens as indicated or remained unsti-
mulated. mICAM-1 was added for the final 4 min of activation.
Blood cells were harvested after different incubation times and
further processed (kinetics are shown in Fig. 1A and represen-
tative examples in Fig. 1B). Unless noted otherwise, the gating
strategy to identify CD8+ T cells is shown in SI Appendix, Fig. S1.
Unstimulated cells showed a very low staining with mICAM-1
(0.01–0.05%), which did not change significantly over time. In
contrast, cells stimulated with SEB or viral peptides were readily
stained by mICAM-1. Of note, different antigen-specific CD8+ T
lymphocytes showed different kinetics of β2-integrin activation:
SEB, NLVPMVATV peptide from CMV pp65, amino acids 495–
503 (CMV/NLV), GLCTLVAML peptide from EBV BMLF1,
amino acids 259–267 (EBV/GLC), and LLWNGPMAV peptide
from YFV NS4B, amino acids 214–222 (YFV/LLW) induced an
immediate peak response within only 4 min. With CMV/pp65 or
HIV/p17 pools of overlapping peptides for stimulation, maxi-
mal staining with mICAM-1 was achieved after 32 min, whereas
1 h was required to detect GILGFVFTL from FLU M1, amino
acids 58–66 (Flu/GIL)-specific cells. Following prolonged
activation with the antigens (>1 h), β2-integrin activation de-
creased again.
Next, we tested the applicability of mICAM-1 staining to de-
tect various frequencies of activated T cells within different cell
preparations.We incubated whole blood from nine CMV-seropositive
Fig. 1. Flow-cytometry assessment of antigen-specific CD8+ T cells using mICAM-1. (A) Time course of activated β2-integrin staining following incubation of
whole blood (WB) without antigen (black, three donors), with SEB (gray, three donors), CMV/NLV peptide (blue, three donors), CMV/pp65 pool of overlapping
peptides (light green, three donors), HIV/p17 pool of overlapping peptides (dark green, one HIV-seropositive patient), EBV/GLC peptide (purple, two donors),
Flu/GIL peptide (red, two donors), or YFV/LLW peptide (orange, one vaccinated subject) for 4, 8, 16, 32, 64, 128, or 256 min. For the final 4 min of incubation,
mICAM-1 was added. Data show percentages of mICAM-1+ cells among total CD8+ T cells; for the antigen-stimulated sample, background from the relevant
unstimulated sample was subtracted (mean ± SEM). (B) mICAM-1 staining obtained from three representative donors after 8 and 64/128 min of stimulation.
(C) Examples of mICAM-1 staining of WB from three CMV-seropositive donors with low, intermediate, and high frequencies of CMV-specific cells after 8-min
stimulation with CMV/NLV peptide. (D) mICAM-1 staining was compared in WB cells, fresh PBMCs and frozen/thawed (fz/thw) PBMCs after 8 min of stim-
ulation with the CMV/NLV peptide. One of two donors is shown. Numbers indicate percentage of mICAM-1+ cells among the CD8+ T cells. w/o, without.



























A2+ donors for 8 min in the presence or absence of the NLV peptide.
Unstimulated cells showed negligible staining with mICAM-1
(≤0.031%), whereas mICAM-1–stained NLV-activated CD8+
T cells made up 0.08–3.8% of total CD8+ T cells. Examples of
mICAM-1 staining for detecting low, intermediate, and high fre-
quencies of CMV-specific T cells are shown in Fig. 1C. In addition to
whole blood, we stained freshly prepared peripheral blood mono-
nuclear cells (PBMCs) and frozen/thawed PBMCs of two additional
donors. The percentages of mICAM-1–stained CD8+ cells were
comparable in all three cell sources, albeit slightly reduced in frozen/
thawed PBMCs (Figs. 1D and 2C). Taking these data together, we
find that mICAM-1 can be used to detect a wide range of frequencies
and specificities of CD8+ T cells in whole blood and in PBMCs at very
early time points of activation.
mICAM-1 Binding Reveals a Subset of pMHC+ CD8+ T Cells. To con-
firm that our method selectively identifies antigen-specific T cells,
we stained blood cells with mICAM-1 and pMHC multimers.
Cells from the same A2+ donors were processed as in the prior
kinetic experiment, but in addition CMV-, EBV-, Flu-, or YFV-
specific cells were detected using staining with A2/NLV, A2/GLC,
A2/GIL, or A2/LLW multimers, respectively (kinetics and repre-
sentative examples are shown in Fig. 2 A and B). Maximal staining
with mICAM-1 was achieved within 4–16 min of activation for
CMV-, EBV-, and YFV-specific cells, and after 1 h for Flu-specific
T cells. Remarkably, the vast majority (90–98%) of mICAM-1+
cells were pMHC multimer-positive. Conversely, most A2/NLV+
cells bound mICAM-1 (70–94%), whereas approximately half of
A2/GLC+ or A2/LLW+ cells and one-quarter of A2/GIL+ cells
were mICAM-1+.
Finally, we stained the cells from 10 prescreened donors with
either pMHC multimers or with mICAM-1 after 8–64 min of
activation with the virus-derived peptides. We observed close-to-
perfect correlation between the frequencies of cells measured
with the two assays, particularly for the CMV-specific cells (r =
0.991, P < 0.001) (Fig. 2C). Hence, our results show mICAM-
1 staining identifies a subset of pMHC+ antigen-specific T cells,
which varies depending on the antigen specificity.
mICAM-1 Binding Identifies Highly Functional Antigen-Specific CD8+ T
Cells. Next, we assessed whether mICAM-1 staining provides
information about the functionality of antigen-specific CD8+
T cells. We examined cytokine production and mobilization of
the degranulation marker CD107a in T cells stimulated with SEB
or viral peptides and costained with mICAM-1. Because β2-
integrin activation displays a different kinetic than cytokine
production or plasma membrane expression of CD107a, we se-
lected stimulation times of 1 and 2 h, after which both a strong
mICAM-1 staining and adequate amounts of cytokines or CD107a
can be simultaneously detected. We observed that irrespective of
antigens used: (i) expression of the functional markers was pre-
dominantly confined to the mICAM-1+ cell fraction; and (ii)
mainly cells with the strongest mICAM-1 binding costained for
the functional markers CD107a, IFN-γ, and TNF (Fig. 3 and SI
Appendix, Fig. S2). Specifically, CD8+ T cells producing at least
one functional marker were for the most part mICAM-1+ after 1 h
(94.7%, as shown in Fig. 3B) or 2 h (85.2%, as shown in SI Ap-
pendix, Fig. S2D) of stimulation with CMV/NLV. Conversely, the
majority of CMV/NLV-stimulated mICAM-1+ T cells, and in
particular the mICAM-1hi population, expressed CD107a, IFN-γ,
and/or TNF after 1 h (Fig. 3 A and B) or 2 h of stimulation (SI
Appendix, Fig. S2 C and D). When we assessed CMV-specific cells
after stimulation with pp65-overlapping peptides, again most cells
expressing at least one of the three functional markers were
mICAM-1+ (93.1% after 1 h and 83.8% after 2 h of stimulation)
(SI Appendix, Fig. S2 B and D). Similar results were obtained with
the other antigen-specificities tested (EBV/GLC, Flu/GIL, or
SEB) (SI Appendix, Fig. S2).
We subsequently analyzed the expression of functional markers
on mICAM-1+ and mICAM-1− pMHC+ cells in the same sub-
jects. We examined every combination of the CD107a, IFN-γ,and
TNF markers after 1 h of stimulation with viral antigens among
the mICAM-1+ and mICAM-1− fractions of A2/NLV+, A2/GLC+,
or A2/GIL+ cells. A representative example for A2/NLV+ cells is
shown in Fig. 3C. Among A2/NLV+ cells, we observed that more
than 60% of mICAM-1+ cells expressed a combination of at least
two functional markers after 1 h of activation, whereas most
mICAM-1− cells were negative for any functional marker (>80%)
(Fig. 3 D and E). Comparable results were obtained for EBV- and
Fig. 2. Comparison of the mICAM-1 and pMHC multimer staining assays. (A) Time course of activated β2-integrin staining after stimulation with CMV/NLV
peptide (blue, three donors), EBV/GLC peptide (purple, two donors), Flu/GIL peptide (red, two donors), or YFV/LLW peptide (orange, one vaccinated subject)
depicted as percentage (mean ± SEM) of the respective pMHC+ CD8+ cells. WB cells from the same donors as in Fig. 1A were stimulated with the indicated
peptides for 4, 8, 16, 32, 64, 128, or 256 min. For the final 4 min of incubation A2/NLV, A2/GLC, A2/GIL, or A2/LLW multimers, respectively, together with
mICAM-1 were added. (B) Responses obtained from three representative donors after 8 or 64 min of incubation. Numbers indicate the percentage of mICAM-
1+ cells among pMHC+ CD8+ T cells. (C) Correlation between antigen-specific CD8+ T cell frequencies as detected by pMHC multimer and mICAM-1 stainings.
WB cells (circles), or (only for CMV) freshly isolated PBMCs (triangles), or frozen/thawed PBMCs (squares) were either stimulated with the indicated peptides
(8 min for CMV, EBV, and YFV and 64 min for Flu) and stained with mICAM-1 or directly stained with the indicated pMHC multimers (in total 10 donors).
Different shapes in the same shade of blue indicate the same donor. The antigens are color-coded as in A. Dashed blue bold line represents the optimal linear
correlation for CMV-specific cells. Bold black line represents the optimal linear correlation across all antigens. p, P value; r, correlation coefficient.
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Flu-specific responses (SI Appendix, Fig. S3 B and D). After 2-h
activation with the various peptides, most mICAM-1+ cells pro-
duced at least two functional markers (60–80%), whereas cells
expressing no functional marker dominated within the mICAM-1−
fraction (45–75%) (SI Appendix, Fig. S3 A, C, and E). Thus,
mICAM-1 staining identifies highly polyfunctional CD8+ T cells
within pMHC+ cells.
mICAM-1 Binding Identifies Functional T Cells of Various Differentiation
Stages.Our data so far indicate that mICAM-1 staining detects the
fraction of antigen-specific CD8+ T cells with immediate function
(Figs. 2 and 3). To further characterize these cells, we used surface
phenotypic (CD27, CD28, and CD45RA) and intracellular cyto-
toxic [granzyme B (GrB) and perforin (Perf)] markers to stain
SEB-stimulated and virus-specific mICAM-1+ CD8+ cells (19).
Approximately 64% of the mICAM-1+ SEB-stimulated CD8+
T cells displayed an intermediate (CD27+CD28−CD45RA+/−) or
late (CD27−CD28−CD45RA+/−) differentiation phenotype (Fig.
4A and SI Appendix, Fig. S4A). Furthermore, most of them
expressed both cytotoxic factors (GrB+Perf+) (SI Appendix, Fig.
S5 A–C), indicating that they were antigen-experienced cytotoxic
effector cells.
To characterize virus-specific CD8+ T cells, blood cells from
A2+ donors were stimulated with CMV/NLV, EBV/GLC (for
8 min), or Flu/GIL (for 1 h) peptides and stained with mICAM-
1, as well as A2/NLV, A2/GLC, or A2/GIL multimers. As shown
previously (19), pMHC+ CD8+ cells varied in their differentiation
phenotype between the different virus specificities. Within the
mICAM-1+ fraction, early-differentiated (CD27+CD28+CD45RA−)
CMV-specific CD8+ T cells were significantly diminished and
those of the intermediate (CD27+CD28−CD45RA−) phenotype
were enriched. Differentiation stages of EBV- and Flu-specific
cells showed a similar distribution within the mICAM-1+ and
mICAM-1− fractions (Fig. 4 B–D and SI Appendix, Fig. S4 B–
D). For the cytotoxic markers, we found that mICAM-1+ cells
Fig. 3. Functional profile of mICAM-1+ T cells. (A) Examples of CD107a,
IFN-γ, and TNF expression by CD8+ T cells after stimulation with the CMV/
NLV peptide for 1 h and staining with mICAM-1 for the final 4 min. Numbers
indicate frequency among CD8+ T cells. (B) mICAM-1 staining among total
CD8+ T cell population (Left), among CD8+ cells producing at least one
functional marker (Center), or among CD8+ cells producing none of them
(Right). Cells expressing at least one functional marker were almost exclu-
sively (94.7%) mICAM-1+, whereas cells expressing none of the markers were
almost exclusively (99.4%) mICAM-1−. Numbers indicate frequency of
ICAM-1+ cells and italic numbers in brackets indicate MFI of mICAM-1. (C)
mICAM-1 vs. A2/NLV staining on CD8+ T cells from the same donor after 1-h
stimulation with the CMV/NLV peptide (final 4 min in the presence of
mICAM-1 and A2/NLV). mICAM-1+ (orange) and mICAM-1− (blue) pop-
ulations are further displayed according to CD107a, IFN-γ, or TNF expression.
(D) Mean ± SEM percentages of mICAM-1+ (orange) and mICAM-1− (blue)
A2/NLV+ T cells showing 3, 2, 1 or no functional markers, obtained in five
donors. (E) The pie charts represent the mean expression of the functional
parameters grouped by number of functions (0–3) among the five donors.
Most of the mICAM-1− A2/NLV+ cells did not produce any functional mark-
ers. *P < 0.05; **P < 0.01; ***P < 0.001 (mICAM-1+ vs. mICAM-1− fractions).
Fig. 4. Expression of differentiation markers according to β2-integrin acti-
vation. (A) mICAM-1 staining after stimulation of WB cells with SEB from one
representative subject is presented as a density plot (Left). Total CD8+ T cells
and the mICAM-1+ fraction were analyzed for CD27, CD28, and CD45RA
expression (a representative example is shown in SI Appendix, Fig. S4A);
mean results are depicted as pie charts (Right). (B–D) mICAM-1 staining on
CD8+ T cells after stimulation of WB from selected A2+ donors with CMV/
NLV (B), EBV/GLC (C), or Flu/GIL peptides (D) (Left). Virus-specific cells were
selected using staining with A2/NLV, A2/GLC, or A2/GIL multimers, and
mICAM-1+ and mICAM-1− fractions were then analyzed for CD27, CD28, and
CD45RA expression (representative density plots are shown in SI Appendix,
Fig. S4 B–D) and are depicted as pie charts (Right). All possible combinations
of CD27, CD28, or CD45RA are shown, with each pie chart representing the
mean percentage of each subset among the indicated number of subjects.
Cells were stimulated for 4 min (SEB, CMV/NLV, or EBV/GLC) or for 1 h (Flu/
GIL), followed by 4-min staining with mICAM-1 and relevant A2/pMHC
multimers. *P < 0.05 (mICAM-1+ vs. mICAM-1− fractions).



























often expressed increased levels of GrB or Perf compared with
mICAM-1− cells (SI Appendix, Fig. S5 D–F). Inversely, GrB−Perf−
cells contained a minority of mICAM-1+ cells (2–20%). Hence,
mICAM-1 staining identifies cells with strong effector func-
tion among memory and effector T cells at different stages of
differentiation.
mICAM-1 Staining Allows Rapid Isolation of Viable Antigen-Specific
CD8+ T Cells with Immediate Effector Functions. We then tested
whether mICAM-1 staining can be used for isolation of pure
population of functional antigen-specific T cells. Fresh PBMCs
from a CMV-seropositive A2+ donor were activated with the NLV
peptide and stained with mICAM-1 and anti-CD8 Ab (Fig. 5A).
Highly enriched fractions of mICAM-1+ CD8+ and mICAM-1−
CD8+ cells were obtained by flow-cytometry sorting (purity
of >90% and 99%, respectively) (Fig. 5B). Staining of the sorted
mICAM-1+ cells with the A2/NLV multimers revealed that they
were mostly (87%) CMV-specific (Fig. 5C). We restimulated the
two fractions with the NLV peptide for 5 h and measured CD107a
expression and cytokine production by intracellular staining.
mICAM-1+ cells were highly enriched for these functional
markers; inversely, mICAM-1− sorted cells neither expressed
CD107a nor produced relevant amounts of cytokines (Fig. 5D).
In a second experiment, we again sorted mICAM-1+ and
mICAM-1− cell populations from the same donor with similar
purities and cultured them in vitro in the presence of anti-CD3
Fig. 5. Functional characterization of sorted mICAM-1+ CD8+ T cells. PBMCs from a CMV-seropositive A2+ donor were cultured without or with the NLV
peptide; the last 4 min in the presence of mICAM-1. (A) Sorting gates for mICAM-1+ CD8+ and mICAM-1− CD8+ cells and (B) immediate postsorting analysis are
shown. Isolated mICAM-1+ and mICAM-1− fractions were then analyzed immediately (ex vivo) or expanded for 10 d in the presence of anti-CD3 Ab, IL-2, and
IL-15 and then analyzed. (C and D) mICAM-1+ sorted (Left) and mICAM-1− sorted (Right) fractions were stained with A2/NLV multimers and analyzed (C) or
stained with A2/NLV multimers, stimulated for 5 h, stained with mICAM-1, and analyzed for functional markers (D). (E and F) Following in vitro expansion for
10 d, mICAM-1+ sorted (Left) and mICAM-1− sorted (Right) fractions were stained with mICAM-1 and A2/NLV multimers after an 8-min stimulation with the
NLV peptide (E) or stimulated for 5 h, stained with mICAM-1, and analyzed for functional markers (F). Numbers indicate the frequency among the sorted
CD8+ T cells.
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antibody, IL-2, and IL-15. Both fractions expanded equally well
(∼500-fold) after 10 d. A short, 8-min reactivation of the expanded
mICAM-1+ and mICAM-1− bulk cells with the NLV peptide and
costaining with A2/NLV and ICAM-1 multimers revealed that
sorted mICAM-1+ cells were almost exclusively (99%) CMV-
specific and the majority were mICAM-1+ (82%). In contrast, a
small proportion (4.4%) of sorted mICAM-1− cells was CMV-
specific (Fig. 5E). Upon restimulation for 5 h in the presence of
the NLV peptide, we found mICAM-1+ cells to be highly functional,
with a 10- to 20-fold enrichment in the expression of CD107a, IFN-
γ, and TNF compared with the mICAM-1− sorted population (Fig.
5F). Similar results, obtained from a second donor are shown in SI
Appendix, Fig. S6. Hence, mICAM-1 staining is suitable for isolating
viable, functional subsets of antigen-specific cells.
Finally, we tested whether the ICAM-1− antigen-specific cells
are nonfunctional or just delayed in their functionality. We first
sorted mICAM-1+ pMHC+ and mICAM-1− pMHC+ CD8 cells
from a CMV-seropositive and a YFV-vaccinated donor after
optimal stimulation with specific peptides. The mICAM-1+
(A2/NLV+ or A2/LLW+) and mICAM-1− (A2/NLV+ or A2/
LLW+) fractions were then additionally cultured for 1 or 5 h and
the functional markers CD107a, IFN-γ, and TNF were analyzed
(Fig. 6). Already 1 h after the stimulation, the majority (90%) of
mICAM-1+ CMV-specific cells and ∼50% of the YFV-specific
cells expressed functional markers (Fig. 6 C and E, respectively).
As expected, a very small amount of CD107a and cytokines were
expressed in the mICAM-1− sorted cells. After 5 h, a further
increase of the functional markers in the mICAM-1+ fraction
Fig. 6. Functional characterization of sorted CMV A2/NLV- or YFV A2/LLW-specific CD8+ T cells according to β2-integrin activation status. PBMCs from a CMV-
seropositive (Left panels) or a YFV-vaccinated A2+ donor (Right panels) were stimulated with the NLV or LLW peptides in the presence of A2/NLV or A2/LLW
multimers and mICAM-1. (A and B) Sorting gates and immediate postsorting analysis for mICAM-1+ and mICAM-1− of A2/NLV+ CD8+ (A) or A2/LLW+ CD8+ cells
(B) are shown. (C–F) mICAM-1+ A2/NLV+ sorted and mICAM-1− A2/NLV+ sorted fractions (C and D) or mICAM-1+ A2/LLW+ sorted and mICAM-1− A2/LLW+
sorted fractions (E and F) were stimulated for 1 (C and E) or 5 h (D and F) and analyzed for functional markers. Numbers indicate the frequency among the
sorted pMHC+ CD8+ T cells. Note, that the 1-h stimulation was in fact 2 h, because it took 60 min from the beginning of the first stimulation—for the sorting—
until the time the sorted cells were placed in the incubator for additional 1-h reactivation.



























was observed, particularly within the YFV-specific cells. Of note,
functional cells were also increased within mICAM-1− sorted
fractions at this time, although their percentages and mean
fluorescent intensities (MFIs) were much lower than in the
sorted mICAM-1+ fractions (Fig. 6 D and F and SI Appendix,
Fig. S7 B and D). The majority of the CD107a- and cytokine-
producing cells within the mICAM-1− sorted cells then also
stained for mICAM-1, suggesting a delayed activation in β2-
integrins coinciding with a delayed and lower production of
functional markers (SI Appendix, Fig. S7).
mICAM-1 Staining for Monitoring Clinical Samples. Finally, we ex-
amined the usefulness of our assay to monitor antigen-specific
CD8+ T cells in cell samples obtained following vaccination of a
healthy subject against yellow fever or from tumor-positive or
HIV+ patients.
Vaccination of a naïve A2+ subject with YFV elicited a strong
CD8+ T cell response detectable ex vivo by mICAM-1 staining
after 8-min activation with the immunodominant LLW peptide.
LLW-specific CD8+ T cells increased from 0.01% before vacci-
nation to 1.16% 2 wk after vaccination, and decreased thereafter
to 0.52% 5 wk after vaccination. In accordance with our previous
results with CMV-, Flu-, and EBV-specific cells, costaining with
A2/LLW multimers revealed that mICAM-1 staining was con-
fined to A2/LLW+ cells and that only a portion of the A2/LLW+
cells (38–44%) were mICAM-1+ (Fig. 7A); mICAM-1+ A2/
LLW+ cells at week 2 postvaccination had an early-differentiated
phenotype (CD27+CD28+CD45RA−) and were highly enriched
for the expression of functional and cytotoxic markers (SI Ap-
pendix, Fig. S8).
We next analyzed PBMC CD8+ T cells obtained from three
prostate cancer patients who had received experimental peptide-
vaccination (20). T cells were first expanded in vitro using the
relevant tumor peptide [i.e., prostate-specific membrane antigen,
ALFDIESKV peptide from PSMA, amino acids 711–719 (PSMA/
ALF), A2 restricted], then restimulated with the same peptide for
4 min, followed by costaining with mICAM-1 and A2/ALF mul-
timers for an additional 4 min. Patient 1 showed higher frequen-
cies of A2/ALF+ cells than patients 2 and 3 (43.4% vs. 26.8% and
10.4%, respectively). In all individuals, a fraction of these cells was
mICAM-1+ (6% vs. 20% vs. 19%), suggesting the assay cannot
only be used to identify tumor-antigen–specific T cells in patients,
but also to assess their functionality (Fig. 7B).
Finally, we evaluated the utility of mICAM-1 staining to
monitor HIV-specific responses in HIV-seropositive patients.
Whole-blood T cells from two recently diagnosed patients were
stimulated ex vivo for 28 min with p17 or Pol overlapping pep-
tides, followed by 4-min staining with mICAM-1. A strong re-
sponse was detected in patient 1 (1.9% and 0.6% of the CD8+
T cell subsets for p17 and Pol, respectively), who had a viral load
of 318 copies per milliliter. In contrast, a negligible percent of
HIV-specific mICAM-1+ CD8+ cells was detected in patient
2 despite a very high viral load of >50,000,000 copies per milli-
liter, strongly suggesting a very recent infection or an ineffective
immune response (Fig. 7C) (21). Confirming the mICAM-
1 staining results, high frequencies of HIV-specific CD8+ T cells,
mainly producing IFN-γ, were detected in patient 1 after 4 h of
stimulation with peptides (1.92% and 0.95% IFN-γ+ and 0.092%
and 0.033% TNF+ cells among the CD8+ fraction following
stimulation with p17 and Pol, respectively), whereas only negli-
gible cytokine production was detected in patient 2 (0.038% and
0.007% IFN-γ+, and 0% and 0% TNF+ cells among the CD8+
fraction following stimulation with p17 and Pol, respectively). Fur-
ther analyses in a third HIV-seropositive patient (viral load of 17,100
copies per milliliter) showed that HIV-specific mICAM-1+ cells
had an intermediate-differentiated phenotype (CD27+CD28−
CD45RA−) and were enriched in cytotoxic markers and cytokine-
producing cells (SI Appendix, Fig. S9). Altogether, these data in-
dicate mICAM-1 staining is a fast and simple method to monitor
functional CD8+ T cell responses in a variety of clinical samples.
Discussion
We introduce a fast and straightforward flow-cytometry method
for the assessment and isolation of live antigen-specific CD8+
T cells, based on the staining of activated β2-integrins with ICAM-1
Fig. 7. mICAM-1 staining of virus- or tumor antigen-specific CD8+ T cells. (A)
YFV vaccination elicits a strong in vivo expansion of LLW-specific CD8+ T cells as
measured by mICAM-1 staining. WB cells from an A2+ vaccinee at baseline
(Upper Left), week 2 (Upper Center), and week 5 (Upper Right) after YFV-
vaccination were stimulated with the LLW peptide for 8 min (final 4 min in
the presence of mICAM-1). Costaining with A2/LLW multimers revealed mICAM-
1+ staining to be specific for the A2/LLW+ cells (Lower). Regular numbers indicate
frequency among CD8+ T cells, italic numbers in brackets indicate frequency of
mICAM-1+ cells among A2/LLW+ cells. (B) PBMCs from three A2+ prostate cancer
patients (Pt) who had received experimental peptide vaccination were expanded
for 12 d in the presence of PSMA/ALF peptide, restimulated for 4 min with the
peptide and stained for 4 min with A2/ALF multimers and mICAM-1. (C) Blood
cells from two HIV+ patients with a viral load of 318 (Upper) or 50,000,000
(Lower) copies per milliliter were incubated without (Left) or in the presence of
peptide pools derived from p17 (Center) or Pol (Right) proteins for 32 min.
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multimers. Our assay is unique because it identifies cells by detecting
immediate changes in the conformation and clustering of a surface
molecule, rather than the up-regulation or production of a protein
that takes significantly longer after stimulation. Hence, compared
with current methods used to detect functional antigen-specific
CD8+ T cells, our assay presents the particular advantage of
requiring activation times of only several minutes, and therefore
of delivering functional information nearly reflecting the in vivo
situation. In contrast, existing techniques to enumerate functional
CD8+ T cells [e.g., intracellular-cytokine staining (22), CD107a
mobilization (4), and CD137 activation (7)] required to culture
the cells for 6–24 h, and—in most cases—to block cellular trans-
port processes and to permeabilize and kill the cells. While pro-
longed incubation times or suboptimal culture conditions might
increase intrinsic background (23), we found that unstimulated
CD8+ cells showed a very low staining with mICAM-1 (0.01–
0.04%), allowing detection of very low frequencies of antigen-
specific cells ex vivo. Another popular assay used to identify
antigen-specific T cells is the direct staining with pMHC multi-
mers; the method is fast and robust, but cannot be used to detect
functional cells, relies on preexisting knowledge about T cell
epitopes, and requires elaborate and costly reagents (24).
Our methodology is applicable for whole blood, freshly iso-
lated or frozen PBMCs, and cultured T cells. It enables the
monitoring of effector cells that respond to a broad range and
format of antigenic stimuli, including virus- and tumor-specific
CD8+ T cells in infectious diseases, cancers, or following pro-
phylactic or therapeutic vaccination. We detected a strong, im-
mediate (within minutes) activation of β2-integrins following
activation with SEB as well as CMV, EBV, YFV, and PSMA 9-
mer immunodominant epitopes. One hour of stimulation was
needed to detect activated integrins after incubation with a Flu
9-mer immunodominant epitope, which might suggest a lower
binding affinity of this peptide to the TCR or a delayed kinetic of
integrin activation for the Flu-specific cells. About 30 min of
incubation was required to reach optimal staining when CMV/
pp65, HIV/p17, or HIV/Pol pools of 15-mer overlapping pep-
tides were used for activation. Because MHC class I molecules
have a closed binding groove, which restricts the length of bound
peptides to about 8–10 residues (25), 15-mer peptides might
require partial processing (i.e., by antigen-presenting cells in the
blood culture).
It was important to compare the assay with available flow-
cytometry techniques. Using different antigens, we showed a
high correlation between mICAM-1 and pMHC stainings. In-
terestingly, only a fraction of the pMHC+ T cells was also stained
with mICAM-1 (between 25% for Flu and 90% for CMV),
suggesting that the remaining pMHC+ T cells were nonfunc-
tional at this time. Sorting of mICAM-1− and mICAM-1+
pMHC+ cells for two model antigens demonstrated that func-
tional cells (producing cytokines and/or expressing CD107a) are
indeed those with early integrin activation. We also observed
that (multi)functional CD8+ T cells with strong cytokine re-
sponses and high CD107a expression were detectable exclusively
within the mICAM-1+ bright fraction, demonstrating that a ro-
bust activation of β2-integrins reveals highly effective, functional
antigen-specific T cells. Similarly, mICAM-1+ T cells showed
enriched coexpression of the two cytotoxic molecules GrB and
Perf. The phenotype of mICAM-1+ T cells, according to surface
expression of CD27, CD28, and CD45RA, ranged from early to
late stages of differentiation and were in line with previously
reported differentiation patterns of CMV-, EBV-, Flu-, YFV-,
and HIV-specific CD8+ T cells (19). Hence, activated β2-integ-
rins mark all T cells with immediate, strong effector function,
irrespective of their differentiation stages. Our preliminary ex-
periments indicate that this is also the case for CD4+ T cells.
Our method preserves cell viability and allows fast and easy
isolation of functional cytotoxic T cells, which puts it in favorable
contrast to time-consuming and elaborate bispecific antibody
capture systems (26). The sorting experiments on antigen-
specific cells show that the mICAM-1+ fraction expresses func-
tional markers, greatly expands in culture, and that sorted cells
retain their functional properties after in vitro expansion. Thus,
the assay should allow the isolation of highly functional CD8+ T
lymphocytes for further gene or protein analysis, as well as for
adoptive transfer (e.g., in clinical settings), because the pro-
cedure and the required reagents accord with GMP standards.
Taken together, our results indicate β2-integrin activation as a
hallmark of immediate T cell functionality, which is detectable at
the very early stages of activation. Staining of β2-integrin acti-
vation is therefore a powerful tool for monitoring and isolating
functional antigen-specific T cells. Because this method is fast,
robust, and versatile, it could also be rapidly implemented for the
measurement of T cells in patient samples in a variety of clinical
settings, for example, during standard or experimental therapy.
Materials and Methods
Study Subjects and Blood Samples. For the studies in healthy individuals, we
selected nine CMV-seropositive, HLA-A2+ subjects with a variable frequency
of CMV A2/NLV multimer+ CD8+ T cells (age range 18–30 y). Additionally,
those individuals with detectable levels of EBV A2/GLC+ or Flu A2/GIL+ CD8+
T cells were used for the assays involving Flu- and EBV-specific CD8+ T cells.
To identify HLA-A2 positivity, we stained with anti–HLA-A2-APC antibody
(clone BB7.2; Biolegend).
Another two healthy HLA-A2+ individuals were subcutaneously vacci-
nated with a single dose of yellow fever vaccine (YF-17D, Stamaril; Aventis
Pasteur MSD) and heparinized blood samples were obtained before and
after vaccination. Cancer patients were taking part in an experimental phase
I/II peptide vaccination study (20). Postvaccination PBMC samples were ac-
cordingly selected (after the 11th, 17th, or 16th vaccinations for patient 1,
patient 2, and patient 3, respectively), thawed, and stimulated for 12 d in the
presence of the relevant peptide and IL-2 before mICAM-1 staining (27).
Blood was also obtained from three recently diagnosed, therapy-naive HIV-
infected patients (HLA not known). The viral loads were 318, 50,000,000, and
17,100 copies per milliliter, and the CD4 cell counts were 727, 571, and
355 cells/mm3, respectively. The precise infection time was not known.
All studies were approved by the Ethics Committee of the University of
Tübingen, and participants gave written informed consent.
Peptides and pMHC Multimers. For antigen-specific stimulation, we used the
following synthetic peptides, representing known immunodominant HLA-
A*02-restricted CD8+ epitopes derived from virus or tumor-associated anti-
gens: NLVPMVATV peptide from CMV pp65, amino acids 495–503 (CMV/NLV),
GLCTLVAML peptide from EBV BMLF1, amino acids 259–267 (EBV/GLC),
GILGFVFTL from FLU M1, amino acids 58–66 (Flu/GIL), LLWNGPMAV pep-
tide from YFV NS4B, amino acids 214–222 (YFV/LLW), and ALFDIESKV peptide
from PSMA, aa 711–719 (PSMA/ALF). All peptides were synthesized and dis-
solved as previously described (28) and were kindly provided by S. Stevanovic,
University of Tübingen, Tübingen, Germany, except for YFV/LLW (JPT Peptide
Technologies). We also used for activation pools of 15-mer peptides over-
lapping by 11 amino acids and spanning the entire CMV/pp65, HIV/p17, or HIV/
Pol proteins. All peptide pools were obtained from JPT, dissolved in DMSO, and
aliquoted and kept frozen at −20 °C until further use.
We produced biotinylated pHLA-A*0201 monomers (CMV A2/NLV, EBV
A2/GLC, Flu A2/GIL, YFV A2/LLW, and PSMA A2/ALF) in-house by conven-
tional refolding, as previously described (29). We generated fluorescent
pHLA-A*0201 multimers by coincubating streptavidin-PE or -APC (Thermo-
fisher) at a 4 (streptavidin):1 (pHLA-A2 monomer) molar ratio. Multimers
were aliquoted and stored at −80 °C in a TBS buffer containing 16% glycerol
(29). The final concentration of azide was 0.035%.
Production of Human ICAM-1 Multimers. Soluble fluorescent ICAM-1 mono-
mers or complexes thereof have been previously used to monitor changes in
β2-integrin affinity induced by activation with chemokines (16), activating
antibodies (30), or using unspecific stimulation in human T cells (18). For our
studies, we generated fluorescent ICAM-1–Fc/anti-Fc multimeric complexes
by coincubating 200 μg/mL recombinant human ICAM-1-Fc [produced and
purified as previously described (31)] with polyclonal anti-human Fc-FITC
F(ab′)2 fragments (Jackson ImmunoResearch) at a 1 (ICAM-1–Fc):2 (IgG part
of anti-Fc–FITC fragments) or 1:4 molar ratios (SI Appendix, Fig. S10A), or
with anti-human Fc-PE F(ab′)2 fragments (Jackson ImmunoResearch) at a 3.4



























(ICAM-1–Fc):1 (PE of anti–Fc-PE fragments) or 1.7:1 molar ratios (SI Appen-
dix, Fig. S10B) at 4 °C for 3 h. We used multimeric ICAM-1 complexes
(mICAM-1) either immediately or stored them in aliquots at −20 °C, for no
more than 2 wk until use. A control solution replacing ICAM-1–Fc with PBS,
thus containing only the fluorescent anti-Fc fragments at the same con-
centration as in the multimeric complexes was used as a negative control in
the titration experiments to assess the unspecific binding (SI Appendix, Fig.
S10, Bottom panels). To establish the optimal mICAM-1working concentra-
tion, we stimulated 380 μL of fresh whole blood from a CMV A2/NLV mul-
timer+ donor with NLV peptide for 8 min. In the final 4 min of activation,
A2/NLV multimers (0.6 μg/mL) and a decreasing concentration of mICAM-1
(in the range of 25–0.78 μg/mL ICAM-1–Fc) were added between min 4 and
min 8. A shorter period of incubation with mICAM-1 (1 or 2 min) yielded a
similar staining but we opted for 4 min to stain simultaneously with pMHC
multimers. The amount of mICAM-1 that resulted in a maximal percentage
of positive cells (>60%) with a low background staining (<0.05%) was
chosen for further experiments (6.25 μg/mL ICAM-1–Fc for ICAM-1–Fc/anti–
Fc-FITC and 3.13 μg/mL ICAM-1–Fc for ICAM-1–Fc/anti–Fc-PE) (SI Appendix,
Fig. S10 A and B, respectively).
Cell Stimulation and mICAM-1 Staining. We used fresh heparinized blood or
PBMCs for the assays.We isolated PBMCs by using Biocoll (Biochrom) gradient
centrifugation. Cells were washed with T cell medium (TCM): IMDM (Lonza)
containing 10% autologous plasma and 1% penicillin/streptomycin (Sigma-
Aldrich). PBMCs were either used immediately or frozen in aliquots in
freezing solution [heat-inactivated FCS (Biochrom) containing 10% DMSO
(Sigma-Aldrich)] and stored in liquid nitrogen until use. Cryopreserved PBMCs
were thawed, washed in TCM, and rested overnight at 37 °C before use.
We stimulated whole blood (380 μL per test) for the indicated times at
37 °C in a water bath in 5-mL Falcon tubes (BD Biosciences) with the fol-
lowing peptides: 4 μg/mL CMV/NLV, 4 μg/mL EBV/GLC, 4 μg/mL Flu/GIL, 4 μg/mL
YFV/LLW, 2 μg/mL PSMA/ALF, peptide pools: 2 μg/mL CMV/pp65, 2 μg/mL HIV/
p17, 2 μg/mL HIV/Pol, or 4 μg/mL SEB (Sigma-Aldrich). For the final 4 min
of incubation, we added mICAM-1/FITC or mICAM-1/PE multimers and
A2/peptide multimers (0.6 μg/mL) as indicated. Immediately after stimulation,
we fixed the samples and lysed erythrocytes with FACS-Lysing solution (BD
Biosciences) containing 1 mM Ca2+ and 2 mM Mg2+ for 5 min, followed by
washing with PBS/0.5% albumin/0.1% sodium azide. After centrifugation, we
stained the cells for surface markers to identify CD8+ T cells: CD3-BV510, CD8-
BV605, CD14-APC-Cy7, and CD19-APC-Cy7 (dump channel) for 15 min at room
temperature. All antibodies used were from by Biolegend. A similar protocol
was applied for PBMCs, stimulating 2 × 106 cells/mL in TCM (380 μL per test).
mICAM-1 and Intracellular Cytokine Staining. For the assessment of in-
tracellular cytokines and CD107amembrane expression, we stimulatedwhole
blood either for 1 or 2 hwith the indicated peptides and concentrations in the
presence of 5 μg/mL brefeldin A (Sigma-Aldrich), 5 μg/mL monensin (Sigma-
Aldrich), and pretitrated amount of CD107-PE-Cy7. For the final 4 min of
incubation, we added mICAM-1 and pMHC multimers as indicated. Imme-
diately after stimulation, we fixed the samples and lysed erythrocytes. The
cells were stained for surface markers to identify CD8+ T cells: CD8-APC, CD3-
AF700, CD14-APC-Cy7, and CD19-APC-Cy7. Cells were then permeabilized
with FACS-Perm2 solution (BD Biosciences) followed by staining for in-
tracellular markers IFN-γ–PerCP–Cy5.5 and TNF-BV605. All antibodies used
were purchased from Biolegend.
mICAM-1 and Differentiation Markers, Intracellular GrB, and Perf Staining. For
surfacemarkers, GrB, and perforin expression, we stimulatedwhole blood for
8min (1 h for the detection of Flu-specific cells) with the indicated antigens. In
the final 4 min of incubation we added mICAM-1, and A2/peptide multimers
as indicated. Immediately after the stimulation period, we fixed the samples
and lysed erythrocytes for 20 min. The cells were stained for surface markers
to identify CD8+ T cells: CD3-BV510, CD8-BV605, CD14-APC-Cy7, and CD19-
APC-Cy7 for 15 min at room temperature. For assessment of cell differenti-
ation, the cells were also stained for the following markers: CD28-BV421,
CD27-APC, and CD45RA-AF700. Alternatively, cells were permeabilized with
FACS-Perm2 solution (BD Biosciences), followed by staining with perforin-
BV421 and GrB-AF647 antibodies for 15 min (Biolegend).
T Cell Sorting and Expansion. PBMCs were isolated by using BD Vacutainer cell
preparation tubes (BD Biosciences). Cells washed in PBS containing 0.5%
albumin, 1 mM Ca2+, and 2 mM Mg2+ (5 × 106 cells/mL, 400 μL per test) were
activated with 4 μg/mL peptide for 16 min (centrifuged prior the activation
at 1,000 × g for 1 min) followed by 4 additional minutes of staining with
ICAM-1 multimers, 4 min of staining with A2/NLV or A2/LLW for the pMHC
sorting experiments (Fig. 6 and SI Appendix, Fig. S7), and 4 min with CD8-
APC (Biolegend) at 37 °C. The sortings for the cell expansion experiments
were performed under the same conditions, except that the cells were ac-
tivated only for 8 min with peptide and not spun down before the activa-
tion. Then the cells were diluted 1:1 with PBS, and immediately sorted on a
BD FACSJazz (BD Biosciences) under sterile conditions. For cell expansion,
isolated mICAM-1+ CD8+ and mICAM-1− CD8+ cells were incubated with
150,000 irradiated (60 Gy) fresh PBMCs from three donors per well of a 96-
well plate in TCM supplemented with 150 U/mL IL-2 (Proleukin; Novartis),
5 ng/mL IL-15 (R&D), and 30 ng/mL anti-CD3 antibody (Miltenyi Biotec), and
incubated for 10 d at 37 °C. Medium was changed every third day and the
cultures were split when necessary. Anti-CD3 antibody was present only in
the initial medium and for the final 3 d of stimulation no cytokines were
added. We isolated 4,000–15,000 mICAM-1+ CD8+ or mICAM-1− CD8+ cells,
and they expanded to 2 × 106 in the 10 d of incubation.
In Vitro Restimulation of the Sorted (and Expanded) CD8+ T Cells. For mICAM-
1+ CD8+ and mICAM-1− CD8+ sorted cells, we first stained with A2/NLV
multimers and then restimulated the freshly isolated or expanded fractions
with the CMV/NLV peptides (4 μg/mL) for 5 h in the presence of 10 μg/mL
brefeldin A (Sigma-Aldrich), 1:1,500 diluted GolgiStop (BD Biosciences), and
CD107-PE-Cy7 (Biolegend). For mICAM-1+ pMHC+ and mICAM-1− pMHC+
sorted cells, the cells were treated as above, except that no CMV/NLV or YFV/
LLW peptides or multimers were added. For antibody staining and analysis
of intracellular IFN-γ and TNF, the cells were treated as described above.
Flow Cytometry and Data Analysis. All antibodies were used at pretested
optimal concentrations. We acquired the data on a LSRFortessa (BD Biosci-
ences) and analyzed it using FACS DiVa v8.0. We collected at least 50,000
CD8+ events for the antigen-specific assays. Results are presented as per-
centage of cells within the parent populations or as MFI. Statistical analyses
were based on paired two-side t tests and Pearson correlation analysis using
IBM SPSS Statistics 22.
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